🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Evaluation of the Effect of a Daily Dose of Wakame Seaweed on Reducing Circulating Concentrations of Advanced Glycation End Products in Patients With Stage III Chronic Kidney Disease

RecruitingNAAges 18 Years - 90 YearsAllGroupe Hospitalier de la Rochelle Ré Aunis
NCT07729683 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Persistent glomerular hyperfiltration is a characteristic feature of the early stages of kidney disease and represents a factor in the progression of chronic kidney disease (CKD). In this context, the benefit of low-protein diets (less than 0.8g/kg/day) has been demonstrated in slowing the progression of CKD, although the underlying pathophysiological mechanisms remain unclear. Some studies suggest that the effects of protein on renal hemodynamics are primarily linked to the quality of the protein, particularly the amount of AGEs (Advanced Glycation End Products) consumed. Recently, edible seaweeds have gained popularity in Western countries due to their anti-inflammatory, anti-diabetic, and antihypertensive properties. These seaweeds are also associated with the above-average longevity of certain Asian populations who consume them daily. Wakame seaweed (Undaria pinnatifida), which is

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Adult patients not under legal protection * Patients aged ≥ 18 and \< 90 years * Patients with stage IIIA-B chronic kidney disease (CKD) (estimated GFR by CKD-EPI ≥ 30 mL/min and \< 60 mL/min) * Patients receiving optimized nephroprotective treatment (ACE inhibitors, SGLT2 inhibitors) * Patients who have signed the informed consent form * Patients not participating in another clinical study * Patients affiliated with or benefiting from a social security scheme Exclusion Criteria: * Adult patients under legal protection * Patients under 18 years old or over 90 years old * Patients with uncontrolled thyroid disorders * Patients with decompensated heart failure * Patients consuming other dietary supplements containing seaweed or iodine (e.g., multivitamins) * Pregnant or breastfeeding women * Patients with acute kidney injury * Patients who decline to participate in the study
💊

What it tests

  • Consumption of wakame
📍

Where

1 site
Groupe Hospitalier de La Rochelle Ré Aunis
La Rochelle, France
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy